🍽️ imatinib,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastrointestinal Disturbances: Common side effects of imatinib include nausea, vomiting, diarrhea, and abdominal pain. These symptoms are usually mild to moderate and can often be managed with supportive care or dose adjustments.
  2. Fluid Retention: Imatinib may cause fluid retention, leading to peripheral edema (swelling of the hands and feet) or fluid accumulation in the lungs (pulmonary edema). Patients should be monitored for signs of edema, and diuretics may be prescribed if necessary.
  3. Musculoskeletal Symptoms: Some individuals may experience muscle cramps, muscle pain, or joint pain while taking imatinib. These symptoms are usually mild and transient.
  4. Fatigue: Fatigue is a common side effect of imatinib therapy. Patients may experience increased tiredness or weakness, which can affect their daily activities.
  5. Hematologic Effects: Imatinib may cause hematologic abnormalities, including anemia (low red blood cell count), thrombocytopenia (low platelet count), or neutropenia (low white blood cell count). Regular blood tests are required to monitor these parameters.
  6. Hepatotoxicity: Imatinib can cause liver toxicity, manifesting as elevated liver enzymes (transaminases) or, rarely, liver damage. Liver function tests should be performed regularly during treatment.
  7. Cardiac Effects: Imatinib may prolong the QT interval, which can increase the risk of cardiac arrhythmias, particularly in patients with preexisting cardiovascular conditions.
  8. Skin Rash: Some patients may develop a skin rash or pruritus (itching) while taking imatinib. These symptoms are usually mild and resolve with continued treatment or symptomatic management.
  9. Endocrine Effects: Imatinib may interfere with thyroid function, leading to hypothyroidism or thyroiditis in some patients. Thyroid function should be monitored periodically during treatment.
  10. Interstitial Lung Disease: Rarely, imatinib may cause interstitial lung disease (ILD), a serious condition characterized by inflammation and scarring of lung tissue. Patients experiencing respiratory symptoms such as dyspnea (shortness of breath) should seek medical attention promptly.
;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of imatinib,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by imatinib,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Agathobacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Roseburia genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Roseburia intestinalis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of imatinib,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.5 0.5
Age-Related Macular Degeneration and Glaucoma 0 0 0
Allergic Rhinitis (Hay Fever) 0 0
Allergy to milk products 0 0
Alopecia (Hair Loss) 0 0
Alzheimer's disease 1.4 -1.4
Ankylosing spondylitis 0 0
Anorexia Nervosa 0 0.5 0
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 0 0
Atherosclerosis 0.1 -0.1
Atrial fibrillation 0.5 0 0
Autism 0.1 1 -9
Bipolar Disorder 0 0 0
Brain Trauma 0 0
Carcinoma 0 0 0
Celiac Disease 0 0
Cerebral Palsy 0 0
Chronic Fatigue Syndrome 0.1 0.1 0
Chronic Kidney Disease 0 0.9 0
Chronic Lyme 0 0
Chronic Obstructive Pulmonary Disease (COPD) 0 0
Coagulation / Micro clot triggering bacteria 0 0 0
Colorectal Cancer 0.1 0.5 -4
Constipation 0 0
Coronary artery disease 0.5 0.5
COVID-19 0.1 1.4 -13
Crohn's Disease 0.1 1 -9
cystic fibrosis 0 0
deep vein thrombosis 0 0
Depression 0.5 1.6 -2.2
Endometriosis 0 0
Epilepsy 0.1 -0.1
Fibromyalgia 0.1 0.1
Functional constipation / chronic idiopathic constipation 0.1 0 0
gallstone disease (gsd) 0 0 0
Graves' disease 0 0 0
Hashimoto's thyroiditis 0 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.5 0.5 0
hyperglycemia 0 0
hypertension (High Blood Pressure 0 0 0
Hypoxia 0 0
Inflammatory Bowel Disease 1.5 -1.5
Insomnia 0 0
Intracranial aneurysms 0 0
Irritable Bowel Syndrome 0 0.1 0
Liver Cirrhosis 0.1 0 0
Long COVID 0.5 0.5 0
Low bone mineral density 0 0
ME/CFS without IBS 0.1 0 0
Metabolic Syndrome 0.1 0.1 0
Mood Disorders 0.5 1.6 -2.2
Multiple Sclerosis 0 1 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 -0.9
Obesity 0.1 0.1 0
obsessive-compulsive disorder 0 0.5 0
Parkinson's Disease 0 0.5 0
Polycystic ovary syndrome 0 0 0
Premenstrual dysphoric disorder 0 0
Psoriasis 0.1 -0.1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.1 0 0
Rosacea 0 0
Schizophrenia 0 0 0
Sjögren syndrome 0 0.5 0
Sleep Apnea 0 0
Stress / posttraumatic stress disorder 0.1 0 0
Systemic Lupus Erythematosus 0 0 0
Type 1 Diabetes 0 0
Type 2 Diabetes 0.1 0.1 0
Ulcerative colitis 0 0.1 0
Unhealthy Ageing 0.9 -0.9

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.